All In Biotech

Drug Trial Radar · NCT06722521

GUIDE-CAC: Statin-Ezetimibe Without Aspirin vs. Statin Monotherapy With Aspirin in High Coronary Calcification

Comparison of Intensive Lipid-Lowering Therapy With a Statin-Ezetimibe Combination (Without Aspirin) vs. Statin Monotherapy (With Aspirin) In Asymptomatic Patient With Coronary Artery Calcification

Last checked: Nov 20, 2026Latest source record: Aug 7, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 7,435 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

7,435

Planned (sponsor's estimate)

Start

Jul 9, 2025

Primary completion

Jun 30, 2032

Study completion Oct 31, 2032

Sponsor

Lead sponsor
Asan Medical CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Dec 9, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Multicenter, randomized trial comparing the efficacy and safety of intensive lipid-lowering therapy using a statin-ezetimibe combination without aspirin versus statin monotherapy with aspirin in asymptomatic patients with coronary artery calcification

Conditions

  • Primary Prevention
  • Vascular Calcification

Interventions

  • Pitavastatin 4mg and ezetimibe 10mg, taken once dailyDrug

    Intensive lipid-lowering therapy without aspirin

  • Pitavastatin 2 mg with aspirin 100 mg, taken once daily.Drug

    Moderate-intensity lipid-lowering therapy with aspirin

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Event rate of a major adverse cardiovascular eventsTime frame: 48months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Asan Medical Center

    Seoul, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.